Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Fidelity leads oversubscribed $55mm Series C round for Afferent

Executive Summary

Afferent Pharmaceuticals Inc. (cardiology, respiratory, neurology, and urology targets in C-fiber primary afferent nerves) closed an oversubscribed $55mm Series C round led by new backer Fidelity Management & Research and including other first-time shareholders Jennison Associates, Partner Fund Management, Redmile Group, Tekla Healthcare Investors, Tekla Life Science Investors, and a blue chip investment fund, plus existing investor New Leaf Ventures.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies